JPIAMR 14th Call Partner Search Tool

This is a match-making section for JPIAMR 14th call - Disrupting drug Resistance Using Innovative Design (DRUID).

General Information

Project title: A first-in-class antibiotic for treatment of antibiotic-resistant Gram-negative infections
Type: Project looking for partner
Organisation: Fedora Pharmaceuticals Inc.
Country: Canada (CA)

Scientific area(s) of the call:
1. Improvement of drug/plant protection agent efficacy and/or specificity through chemical modifications (including hit to lead optimisation)
One Health Setting:
Human Health
Type of studies/experimental approaches:
in silico, in vitro, in vivo preclinical and clinical studies in human and in all veterinary settings
Keywords:
antibiotic; PBP; Mechanism; prodrug;
Brief description of your expertise / expertise you are looking for:
- Testing against larger sets of clinical isolates-Gram Negative - Mechanism of action studies - in silico modeling to support MoA - Animal efficacy studies in various animal infection models - Prodrug formulations
Brief description of your project / the project you would like to join:
Fedora is developing a first-in-class small molecule direct-acting antibiotic for treatment of resistant Gram-negative bacterial infections. Fedora\'s lead compounds exhibited both in vivo efficacy and safety profiles in appropriate animal models/studies. Preclinical studies are set to begin in 2022 with first-in-man dosing set for 2023.

Submitted on 2022-01-12 05:16:30